$PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.

2016 Q3 Form 10-Q Financial Statement

#000119312516676932 Filed on August 09, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.320M $3.040M $2.370M
YoY Change 14.09% 28.27% -20.2%
% of Gross Profit
Research & Development $2.461M $2.005M $2.225M
YoY Change -14.07% -9.87% 116.92%
% of Gross Profit
Depreciation & Amortization $160.0K $180.0K $180.0K
YoY Change 0.0% 0.0% 5.88%
% of Gross Profit
Operating Expenses $5.777M $5.045M $4.592M
YoY Change -0.03% 9.86% 10.38%
Operating Profit -$5.777M -$5.045M -$4.592M
YoY Change -0.03% 9.87% 10.38%
Interest Expense $340.0K $0.00 $50.00K
YoY Change -100.0% -98.58%
% of Operating Profit
Other Income/Expense, Net -$99.00K $1.000K $47.00K
YoY Change 9800.0% -97.87% -98.66%
Pretax Income -$5.880M -$5.040M -$4.540M
YoY Change 1.73% 11.01% 609.38%
Income Tax
% Of Pretax Income
Net Earnings -$5.876M -$5.044M -$4.545M
YoY Change 1.66% 10.98% 606.84%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$26.37K -$23.68K -$24.18K
COMMON SHARES
Basic Shares Outstanding 212.8M shares 212.8M shares 204.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.180M $4.890M $23.12M
YoY Change -72.56% -78.85% 27.52%
Cash & Equivalents $5.178M $4.891M $23.12M
Short-Term Investments
Other Short-Term Assets $187.2K $316.6K $1.186M
YoY Change -82.44% -73.3%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.415M $5.408M $24.50M
YoY Change -72.86% -77.93% 35.18%
LONG-TERM ASSETS
Property, Plant & Equipment $75.22K $78.15K $85.79K
YoY Change -15.14% -8.91% 221.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $27.00K $27.00K $27.00K
YoY Change 0.0% 0.0% 0.0%
Total Long-Term Assets $5.270M $5.421M $6.739M
YoY Change -20.8% -19.56% 69.63%
TOTAL ASSETS
Total Short-Term Assets $5.415M $5.408M $24.50M
Total Long-Term Assets $5.270M $5.421M $6.739M
Total Assets $10.69M $10.83M $31.24M
YoY Change -59.84% -65.34% 41.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.490M $770.0K $520.0K
YoY Change 53.61% 48.08% 8.33%
Accrued Expenses $550.0K $920.0K $470.0K
YoY Change -49.54% 95.74% 38.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.376M $1.689M $988.5K
YoY Change 159.12% 70.84% 21.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $10.00K
YoY Change -99.23%
Total Long-Term Liabilities $0.00 $0.00 $10.00K
YoY Change -100.0% -99.23%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.376M $1.689M $988.5K
Total Long-Term Liabilities $0.00 $0.00 $10.00K
Total Liabilities $5.380M $1.690M $995.4K
YoY Change 159.32% 69.77% -53.03%
SHAREHOLDERS EQUITY
Retained Earnings -$200.2M -$194.3M -$165.4M
YoY Change 16.99% 17.53% 7.83%
Common Stock $243.9K $212.8K $204.6K
YoY Change 19.18% 4.04% 15.81%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.310M $9.140M $30.25M
YoY Change
Total Liabilities & Shareholders Equity $10.69M $10.83M $31.24M
YoY Change -59.84% -65.34% 41.37%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$5.876M -$5.044M -$4.545M
YoY Change 1.66% 10.98% 606.84%
Depreciation, Depletion And Amortization $160.0K $180.0K $180.0K
YoY Change 0.0% 0.0% 5.88%
Cash From Operating Activities -$5.000M -$4.870M -$4.030M
YoY Change 18.2% 20.84% 17.84%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.280M 0.000 12.97M
YoY Change -100.0% 164.69%
NET CHANGE
Cash From Operating Activities -5.000M -4.870M -4.030M
Cash From Investing Activities 0.000 0.000
Cash From Financing Activities 5.280M 0.000 12.97M
Net Change In Cash 280.0K -4.870M 8.940M
YoY Change -106.6% -154.47% 504.05%
FREE CASH FLOW
Cash From Operating Activities -$5.000M -$4.870M -$4.030M
Capital Expenditures $0.00
Free Cash Flow -$5.000M
YoY Change 18.48%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
59861601 shares
CY2015Q4 pvct Class Of Warrant Or Right Discounted Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightDiscountedExercisePriceOfWarrantsOrRights
0.50
CY2015Q4 pvct Class Of Warrant Or Right Cash Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCashExercisePriceOfWarrantsOrRights
0.85
CY2016Q2 pvct Number Of Shares Issuable On Exercises Of Warrants Issued
NumberOfSharesIssuableOnExercisesOfWarrantsIssued
51149594 shares
CY2016Q2 pvct Class Of Warrant Or Right Discounted Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightDiscountedExercisePriceOfWarrantsOrRights
0.75
CY2016Q2 pvct Class Of Warrant Or Right Cash Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightCashExercisePriceOfWarrantsOrRights
0.85
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
212829352 shares
CY2013Q2 us-gaap Litigation Reserve
LitigationReserve
100000
CY2016Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7798507 shares
CY2014Q2 us-gaap Loss Contingency Receivable
LossContingencyReceivable
2240000
CY2014Q2 pvct Reimbursement Receivable Percentage
ReimbursementReceivablePercentage
0.25 pure
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23117144
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
458020
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
212829352 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
212829352 shares
CY2016Q2 us-gaap Assets
Assets
10828876
CY2016Q2 us-gaap Assets Current
AssetsCurrent
5407898
CY2016Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10828876
CY2015Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8802857
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4891313
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
212829
CY2016Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
773093
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
192000
CY2016Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
203273872
CY2016Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2016Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
9138417
CY2016Q2 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
200000
CY2016Q2 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
683250
CY2016Q2 us-gaap Other Assets Current
OtherAssetsCurrent
316585
CY2016Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2577028
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1688710
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
723617
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
78153
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
9140166
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-194346535
CY2016Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q2 pvct Litigation Settlement Remaining Reserve
LitigationSettlementRemainingReserve
870578
CY2016Q2 pvct Litigation Settlement Remaining Balance Due
LitigationSettlementRemainingBalanceDue
2255547
CY2016Q2 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
2055547
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17391601
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
451028
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
204979100 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
204979100 shares
CY2015Q4 us-gaap Assets
Assets
20439812
CY2015Q4 us-gaap Assets Current
AssetsCurrent
14720094
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14178902
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
204979
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1887171
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
133282
CY2015Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
196908112
CY2015Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2015Q4 us-gaap Settlement Liabilities Current
SettlementLiabilitiesCurrent
1850000
CY2015Q4 pvct Long Term Receivable Reimbursable Legal Fees
LongTermReceivableReimbursableLegalFees
2011735
CY2015Q4 us-gaap Loss Contingency Receivable Current
LossContingencyReceivableCurrent
500000
CY2015Q4 us-gaap Loss Contingency Receivable Noncurrent
LossContingencyReceivableNoncurrent
683250
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
41192
CY2015Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20439812
CY2015Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2912588
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4122871
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
252418
CY2015Q4 us-gaap Litigation Reserve
LitigationReserve
227750
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
27000
CY2015Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
85145
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
16316941
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-180796150
CY2015Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2015Q4 pvct Number Of Shares Issuable On Exercises Of Warrants Issued
NumberOfSharesIssuableOnExercisesOfWarrantsIssued
59861601 shares
CY2016Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3899254
CY2016Q1 pvct Class Of Warrant Or Right Number Of Warrants Issued During Period
ClassOfWarrantOrRightNumberOfWarrantsIssuedDuringPeriod
7798507 shares
CY2014Q2 us-gaap Loss Contingency Damages Paid Value
LossContingencyDamagesPaidValue
1120000
CY2014Q2 pvct Future Payments Ratio Of Contingent Consideration
FuturePaymentsRatioOfContingentConsideration
2 pure
CY2014Q2 pvct Annual Cash Bonus Percentage
AnnualCashBonusPercentage
0.70 pure
CY2014Q3 pvct Attorneys Fees Awarded By Court In Legal Settlement
AttorneysFeesAwardedByCourtInLegalSettlement
911000
CY2014Q4 pvct Share Based Compensation Arrangement By Share Based Payment Award Options Settlements In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSettlementsInPeriod
2800000 shares
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5725543
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4539026
us-gaap Depreciation
Depreciation
6378
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
335560
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-139594
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
55214
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
62918
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
77836
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
207801
us-gaap Net Income Loss
NetIncomeLoss
-9070056
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-533333
us-gaap Operating Income Loss
OperatingIncomeLoss
-9212135
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
13944755
us-gaap Investment Income Interest
InvestmentIncomeInterest
2485
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8219212
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4673109
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
186501656 shares
pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
139594
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
127000
pvct Net Proceeds From Sales Of Common Stock And Warrants
NetProceedsFromSalesOfCommonStockAndWarrants
13653927
pvct Proceeds From Exercises Of Warrants And Stock Options
ProceedsFromExercisesOfWarrantsAndStockOptions
290828
pvct Interest And Taxes
InterestAndTaxes
0
dei Entity Registrant Name
EntityRegistrantName
PROVECTUS BIOPHARMACEUTICALS, INC.
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000315545
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-9287589
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9139106
us-gaap Depreciation
Depreciation
6992
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
335560
us-gaap Revenues
Revenues
0
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
529917
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1114078
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
275393
us-gaap Net Income Loss
NetIncomeLoss
-13550385
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-256188
us-gaap Operating Income Loss
OperatingIncomeLoss
-13552052
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
3635040
us-gaap Investment Income Interest
InvestmentIncomeInterest
1667
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-12922629
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <u>Estimates</u></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
dei Trading Symbol
TradingSymbol
PVCT
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4412946
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
209053930 shares
pvct Litigation Settlement Present Value Of Discount Remaining
LitigationSettlementPresentValueOfDiscountRemaining
153874
pvct Litigation Settlement Payment Description
LitigationSettlementPaymentDescription
The remaining cash settlement amounts will continue to be repaid to the Company over a period of four years with the second payment due in total by October 2016 and the final payment is expected to be received by October 3, 2019. $150,000 was repaid by the Executives during the three months ended June 30, 2016, and a total of $300,000 was repaid for the six months ended June 30, 2016. An additional $21,258 of the settlement discount was amortized as of June 30, 2016, and a total of $43,812 was amortized for the six months ended June 30, 2016. $147,781 of the settlement discount was amortized as of June 30, 2016.
pvct Issuance Of Stock For Services
IssuanceOfStockForServices
20163
pvct Increase Decrease In Accrued Settlement Expenses
IncreaseDecreaseInAccruedSettlementExpenses
-1850000
pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
147781
pvct Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
3635040
pvct Warrant Incentive Expense
WarrantIncentiveExpense
2718407
pvct Interest And Taxes
InterestAndTaxes
0
pvct Litigation Settlement Amortization Amount
LitigationSettlementAmortizationAmount
43812
CY2015Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1632
CY2015Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
3000 shares
CY2015Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
3693898 shares
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2367041
CY2015Q2 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
53582
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-4544949
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4591664
CY2015Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
1147
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2224623
CY2015Q2 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
75000 shares
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
187792643 shares
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsIssued
100000 shares
CY2015Q2 pvct Gain Loss On Change In Fair Value Of Warrant Liability
GainLossOnChangeInFairValueOfWarrantLiability
45568
CY2015Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1161790 shares
CY2016Q1 us-gaap Share Based Goods And Nonemployee Services Transaction Quantity Of Securities Issued
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfSecuritiesIssued
51745 shares
CY2016Q1 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1048494 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3039874
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-5044082
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5044836
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
754
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2004962
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3830000 shares
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
212829352 shares
CY2016Q2 pvct Share Based Goods And Nonemployee Services Transaction Quantity Of Warrants Expired
ShareBasedGoodsAndNonemployeeServicesTransactionQuantityOfWarrantsExpired
1757253 shares
CY2016Q2 pvct Litigation Settlement Amortization Of Discount
LitigationSettlementAmortizationOfDiscount
21258

Files In Submission

Name View Source Status
0001193125-16-676932-index-headers.html Edgar Link pending
0001193125-16-676932-index.html Edgar Link pending
0001193125-16-676932.txt Edgar Link pending
0001193125-16-676932-xbrl.zip Edgar Link pending
d217898d10q.htm Edgar Link pending
d217898dex311.htm Edgar Link pending
d217898dex312.htm Edgar Link pending
d217898dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
pvct-20160630.xml Edgar Link completed
pvct-20160630.xsd Edgar Link pending
pvct-20160630_cal.xml Edgar Link unprocessable
pvct-20160630_def.xml Edgar Link unprocessable
pvct-20160630_lab.xml Edgar Link unprocessable
pvct-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending